Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice

For patients with locally advanced or metastatic melanoma who have BRAF V600 activating mutations, combination therapy with BRAF and MEK inhibitors is now the standard of care. The combination of encorafenib, a highly selective adenosine triphosphate–competitive BRAF inhibitor, plus binimetinib, a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Augustyn, Kourtney, Joseph, Jocelyn, Patel, Anisha B., Razmandi, Azadeh, Ali, Amatul Noor, Tawbi, Hussein A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470431/
https://www.ncbi.nlm.nih.gov/pubmed/37534686
http://dx.doi.org/10.1097/CMR.0000000000000891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470431/
https://www.ncbi.nlm.nih.gov/pubmed/37534686
http://dx.doi.org/10.1097/CMR.0000000000000891

Ejemplares similares